The Importance of the Pathological Perspective in the Management of the Invasive Lobular Carcinoma

Funda Tasli,1 Demet Cavdar,1 Sibel Demir Kececi,2 Baha Zengel,1 Zehra Hilal Adibelli,1 Gamze Dal,1 Irem Gonen,1 Ozden Oz,1 Cengiz Yilmaz,1 Ozlem Ozdemir,1 Hulya Mollamehmetoglu,1 Ismail Dilek,3 Enver Ilhan,1 and Adam Uslu1

1Health Sciences University, Izmir Faculty of Medicine, Department of Pathology, Izmir Faculty of Medicine Bozyaka Training Hospital, Izmir, Turkey
2Manisa Merkez Efendi Hospital, Department of Pathology, Manisa Merkez Efendi State Hospital, Manisa, Turkey
3Igdir State Hospital, Department of Radiology, Pr Sultan Abdal, Melekli Street, Igdir, Turkey

Correspondence should be addressed to Funda Tasli; fundadr@gmail.com

Received 29 April 2022; Accepted 8 September 2022; Published 26 September 2022

Academic Editor: Taobo Hu

Copyright © 2022 Funda Tasli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Invasive lobular carcinomas (ILC) account for 10–15% of all breast cancers and are the second most common histological form of breast cancer. Classical ILC is characterized by the characteristic single-row formation of discohesive cells that infiltrate the breast stroma without producing desmoplastic stroma. Cells are often dispersed separately along a fibrous form of breast cancer. Classical ILC is characterized by the characteristic single-row formation of discohesive cells that infiltrate the breast stroma without producing desmoplastic stroma. Cells are often dispersed separately along a fibrous form of breast cancer.

1. Introduction

Invasive lobular carcinomas (ILC) account for 10–15% of all breast cancers and are the second most common histological form of breast cancer. Classical ILC is characterized by the characteristic single-row formation of discohesive cells that infiltrate the breast stroma without producing desmoplastic stroma. Cells are often dispersed separately along a fibrous form of breast cancer.
connective tissue or organized into single-row linear cords that invade the fibrous stroma [1–3]. The developmental pattern of classical single cell infiltrates in the ILC and the lack of stromal reactions make it difficult to determine the size of the tumor and its boundaries within the breast parenchyma [4]. Mostly, the immune response to the tumor is minimal. ILC is often associated with lobular carcinoma in situ. It is now recognized as a biologically distinct disease from the more common invasive ductal carcinoma [1–3].

Intraoperative resection margin assessment is widely used in the breast-conserving surgery (BCS) procedure, as it significantly reduces reoperation rates, and many techniques have been developed for this [5]. The techniques frequently reported in the literature are frozen section analysis and imprint cytology. The frozen section is the most commonly used method in the BCS procedure. In this technique, the sample is frozen and sectioned, followed by microscopic examination by thawing, fixing, and staining [6]. Tubular carcinoma and ILC are reported to be the most common mammary tumors that may have diagnostic difficulties in frozen section examination. Freezing and microscopic examination of all borders may cause erroneous results, especially due to difficulties in freezing and sectioning of adipose tissue. In frozen evaluation; Factors such as freezing and thawing artifact, irregular surface of the breast tissue, and thermal damage of the breast parenchyma caused by electrocautery, especially at surgical margins, may complicate the evaluation of surgical margins in frozen for some tumors such as ILC [7].

Safe surgical margins for the BCS procedure are defined in the 2014 Society of Surgical Oncology (SSO)-American Society for Radiation Oncology (ASTRO) guidelines as “no tumor cells in the ink” for all invasive breast carcinomas, including the invasive lobular subtype. Retrospective studies that provided guidelines for the lobular subtype examined tumor recurrence, disease-free, and overall survival in the same breast, and reported similar results in ductal and lobular carcinomas [8–11]. However, in these studies, the lobular subtype is approximately 10% of the patient population, and the necessity and frequency of reoperation have not been discussed.

In this study, we aimed to investigate how the pathological evaluation in the frozen session shapes the surgical procedure, the results of the surgical approach, and the difficulties and pitfalls in the practice of pathology in patients with a diagnosis of ILC who underwent BCS.

2. Materials and Methods

2.1. Study Population. The study included 79 cases diagnosed with invasive lobular carcinoma by a Tru-cut biopsy and operated in our center between 2014 and 2021. The radiological findings of the cases, the surgical procedures performed, age, tumor size, lymph node status, multifocality, presence of in situ lesions, molecular subtype, neoadjuvant status (yes/no), type of surgery (breast-conserving surgery/complementary mastectomy/mastectomy), conservative surgery performed cavity revision request in frozen session in cases, presence of tumor in revision (presence/absent), compatibility in radiological and pathological treatment response evaluation in cases who received neoadjuvant treatment were examined.

2.2. Pathological Examination. In the BCS procedure, the lumpectomy materials sent to the pathology laboratory for intraoperative pathological analysis, oriented with sutures, were first positioned according to the sutures and evaluated considering 6 surgical margins (anterior, posterior, lateral, medial, superior, and inferior). The outer surface of the material is painted with ink for surgical margins. After the ink was dried, 5 mm thick sections were made on the material in the anterior-posterior plane. The dimensions of the observed tumor and its distance from the surgical margins were determined macroscopically. Samples were taken for microscopic examination from the nearest surgical margins and fibrotic areas at the surgical margins in palpable tumor-free materials.

After the samples were frozen in the frozen device, 5 micron thick sections were obtained, and they were taken on the preparations and stained with hematoxylin and eosin staining. Stained preparations were evaluated by 2 expert pathologists. Although the duration of the frozen procedure varies only when accompanied by surgical margin evaluation or sentinel sampling, it is around 15 minutes on average. The 2014 ASCO/ASTRO guideline was based on the evaluation of surgical margin positivity.

| Table 1: Clinical and biological characteristics of the cases. |
|-----------------|-----------------|
| Tumor characteristics | Cases |
| Age average | 60.51 ± 13.64 |
| Mastectomy | BCS |
| Molecular subtypes | |
| Luminal A | 50 |
| Luminal B | 29 |
| Multifocality | |
| Presence | 37 |
| Absent | 42 |
| In situ component | |
| Presence | 50 |
| Absent | 29 |
| T stage | |
| T1 | 27 |
| T2 | 44 |
| T3 | 8 |
| Nodal stage | |
| N0 | 40 |
| N1 | 20 |
| N2 | 11 |
| N3 | 8 |
| Neoadjuvant treatment | |
| Presence | 12 |
| Absent | 67 |
| Surgical procedure applied | |
| Mastectomy | 27 |
| BCS | 52 |
| Completion mastectomy | 18 |
2.3. Statistical Analysis. Statistical analyzes were performed using the SPSS 21.0 software for Windows. All statistical tests were two-sided, and a p value < 0.05 was considered statistically significant.

Quantitative variables were compared by Pearson’s chi-square test. Qualitative variables were compared by the variance analysis (ANOVA). For non-normally distributed variables, a nonparametric analysis was performed (Mann–Whitney U test). A logistic regression model was used for multivariate analysis.

3. Result

All 79 cases were female. The youngest age was 36, the highest was 82 and the mean age was 59 and 48 years. Twenty (25.3%) of the cases are under the age of 50. The clinical and biological characteristics of the cases are summarized in Table 1. When the entire patient population was evaluated; mastectomy was performed in 27 patients (34.2%) and breast-conserving surgery (BCS) was performed in 52 patients (65.8%). In the cases that underwent mastectomy and BCS; there is statistical significance with the presence of in situ component and tumor size (p < 0.05).

Cavity revision was performed in 8 (15.4%) of 52 patients who underwent BCS, and completion mastectomy was performed in 18 (34.6%) patients. In other words, an additional surgical procedure was performed for safe surgical margins in 26 (50%) of the patients who underwent BCS. The need for additional surgical procedures in BCS cases was evaluated with multifocality, tumor size, presence of in situ component, lymph node metastasis, and neoadjuvant treatment (Table 2). Additional surgery was found to be statistically significant in those receiving neoadjuvant treatment (p < 0.05). There was also statistical significance between tumor size and additional surgery (p < 0.05). The presence of in situ components, lymph node status, and multifocality are unrelated to additional surgery.

No tumor was detected in the reoperation materials in 12 (46.1%) of 26 patients who underwent cavity revision or completion mastectomy. There is statistical significance between the presence of tumor and tumor size in the reoperation materials (p < 0.05). Multifocality, neoadjuvant therapy, lymph node status, and presence of in situ components are not associated with the presence of residual tumor in additional surgical material.

There are 12 patients in our series who received neoadjuvant therapy. No pathological complete response was observed in any patient, and 9 (75%) had no response and 3 (25%) had a partial response. When radiological response evaluation and pathological response were compared after neoadjuvant therapy; All 7 cases, which were evaluated as radiological complete-near complete response, were pathologically unresponsive. Additional surgical procedure (complementary mastectomy or cavity revision) was performed in 6 (85.7%) of 7 patients who underwent BCS. Neoadjuvant therapy uptake and surgical procedures performed in the entire patient population are summarized in Table 3.

4. Discussion

BCS is defined as the removal of the tumor along with the surrounding normal breast tissue without impairing the cosmetic appearance of the breast [12]. It is the primary treatment for early-stage breast cancer. The most commonly used method for the evaluation of intraoperative surgical margins is the “frozen section” method [5]. Nowikiewicz et al. reported that the intraoperative frozen evaluation method reduces the frequency of reoperation in lumpectomy patients. But only 8% of the study population has ILC patients and the frequency of reoperation according to histological subtypes has not been reported [6]. Additional surgical procedures in ILC are reported in the literature at a rate of 23.1%–44.5% [2, 13]. In their study, Hewit et al. reported that 10.6% of ILC patients who underwent total mastectomy had positive surgical margins and that surgical margin positivity was associated with large tumor size and short recurrence-free survival [14].

In our study, surgical margin positivity was not found in cases with primary mastectomy. All 52 patients who underwent BCS were evaluated with the intraoperative frozen section in terms of surgical margins, and 26 (50%) of 52 patients underwent additional surgical procedures due to positive surgical margins. There is a relationship between large tumor size and additional surgical procedures. The high rate of need for additional surgery in our study, which is similar to the literature, may be related to the fact that tumors are not suitable for frozen evaluation due to the different histological patterns of the tumor. If we discuss the ILC surgical margin evaluation from a pathological point of view (1) frozen surgical margin assessment begins with the identification of the invasive margins of the tumor by palpation and macroscopic examination. The pathological response to invasion is the disorganized arrangement of tumor cells with a desmoplastic reaction that gives the tumor its stiffness. Tumors cannot be localized by palpation because the stromal reaction is not usually expected in ILC. Since the tumor spreads along the fibrotic bands of the usual breast parenchyma, it is often not confined and it is difficult to determine the sampling site for microscopic examination. (2) BCS materials do not have a smooth surface as the parenchyma consists of adipose tissue. The penetration of the ink applied for the surgical margin into the fat lobules may make it difficult to determine the true resection margin (Figure 1). (3) Electrocautery used during surgery causes thermal burns in the tissue. This artifact that occurs at the surgical margins disrupts the structural and cytological details of the cells (Figure 2). The hypocellular nature of the tumor and the quiescent nuclear features seen in ILC may cause the tumors to mix with lymphocytes dispersed as a single cell (Figure 3). (4) Frozen process damages the tissue by freezing and thawing processes, especially in fatty tissues, this damage can result in tissue loss and failure in sectioning (Figure 4). In addition, it is statistically significant to apply more additional surgical procedures to those receiving neoadjuvant therapy in our study. After neoadjuvant therapy, fibrosis occurs in the surrounding breast parenchyma as well as the tumor [15]. Therefore, it is expected that
increased fibrosis and degenerative changes in tumor cells due to neoadjuvant therapy in the fibroadipous parenchyma will make the differentiation of the tumor more difficult (Figure 5).

Even if a clear margin is obtained as a result of the intraoperative frozen evaluation, 10% false negativity is reported in the histopathological examination of the permanent tissue [16, 17]. Intraoperative surgical margin assessment in this histological subtype is performed with a small number of samples in narrow areas, which raises some doubts about the safety of its resection [18]. In the studies of Piper et al., the intraoperative positive margin rate in ILC is reported to be 37.6% [19].

In our study, surgical margins were positive in 26 (50%) of 52 cases in the frozen session. Cavity revision was performed in 8 patients (30.8%) who underwent additional surgery, and completion mastectomy was performed in 18 patients (69.2%). However, in 7 of 8 patients who underwent cavity revision and 5 of 18 patients who underwent completion mastectomy, no tumors were detected in the reoperation materials in the permanent sections. In our study, the rate of tumor absence in the reoperation materials was 46.1%, and a small tumor size was found to be associated with our series. This high rate may be due to the freezing artifacts formed in the tissue in the frozen session, the single tumor cells becoming more obscure, the confusion of tumor cells with inflammatory or stromal cells, and the complete deletion of cellular details at the surgical margins. Furthermore, it should be kept in mind that tumor sampling from the correct area may not be performed in the frozen session, since the absence of a stromal reaction in the tumor causes the invasive edges of the tumor to not be evaluated clearly. It was thought that the absence of tumor in the permanent sections in 5 of 18 cases who underwent complementary mastectomy may be due to false positives in the frozen evaluation, as well as sampling errors in the permanent tissue. Complete sampling and histopathological examination of the mastectomy material is not possible in

| Cases                   | Receiving neoadjuvant therapy | Not receiving neoadjuvant therapy | Total |
|-------------------------|------------------------------|----------------------------------|-------|
| Mastectomy              | 5                            | 22                               | 27    |
| BCS                     | 7                            | 45                               | 52    |
| Additional surgery after BCS | 6                            | 20                               | 26    |
| Total                   | 12                           | 67                               | 79    |

### Table 2: Clinicopathological features of patients who underwent BCS.

| Age          | Only lumpectomy | Cavity revision | Additional surgery | Completion mastectomy |
|--------------|-----------------|-----------------|--------------------|-----------------------|
| Under 50     | 6               | 1               | 5                  | 12                    |
| Over 50      | 20              | 7               | 13                 | 40                    |
| Tumor size   |                 |                 |                    |                       |
| T1           | 13              | 5               | 4                  | 22                    |
| T2           | 13              | 3               | 11                 | 27                    |
| T3           | 0               | 0               | 3                  | 3                     |
| Multifocality|                 |                 |                    |                       |
| Presence     | 8               | 2               | 11                 | 21                    |
| Absent       | 18              | 6               | 7                  | 31                    |
| Neoadjuvant treatment|            |                 |                    |                       |
| Presence     | 1               | 2               | 4                  | 7                     |
| Absent       | 25              | 6               | 14                 | 45                    |
| In situ component|            |                 |                    |                       |
| Presence     | 15              | 5               | 13                 | 33                    |
| Absent       | 11              | 3               | 5                  | 19                    |
| Total        | 26              | 8               | 18                 | 52                    |

### Table 3: Surgical procedures performed in patients who received and did not receive neoadjuvant.

Figure 1: Penetration of ink between oil lobules (x40, H&E).
terms of the functioning of the pathology laboratory, time, and cost. Therefore, since mastectomy specimens were not completely sampled, it was thought that the tumor might not have been detected in the permanent sections.

Regarding neoadjuvant therapy in invasive lobular carcinomas, many retrospective studies and meta-analyses report low pathologic complete response, high positive surgical margin, and low clinical response compared to ductal carcinoma, and neoadjuvant therapy is considered a relative contraindication [20–24]. The pathological complete response rate of neoadjuvant therapy varies between 1 and 7.4% in the literature [20, 22–24]. In our study, no pathological complete response was observed in any of the 12 patients who received neoadjuvant therapy in our population. However, in radiological response evaluation, 7 (58.3%) of 12 patients had a complete response and 3 (25%) had a partial response. Pathological diagnostic difficulties arising from the unique pattern of the tumor in ILC are also reported in its radiological diagnosis [25]. The difference in the evaluation of pathological and radiological responses in our series causes us to think that residual breast follow-up may be difficult in patients undergoing BCS, even if a safe margin is achieved surgically.

In our series, the need for additional surgery was not found to be statistically significant between the patients who received and did not receive neoadjuvant therapy, due to the low number of cases. BCS was initially applied to 7 (58.3%) of the patients who received neoadjuvant therapy. An additional surgical procedure was performed in 6 (85.7%) of 7 patients who underwent BCS, and 4 patients (57.1%) underwent a complementary mastectomy. Boughey et al., in their study, investigated the frequency of BCS in ILC patients who received and did not receive neoadjuvant therapy. An additional surgical procedure was performed in 6 (85.7%) of 7 patients who underwent BCS, and 4 patients (57.1%) underwent a complementary mastectomy. Boughey et al., in their study, investigated the frequency of BCS in ILC patients who received and did not receive neoadjuvant therapy. In this study, BCS was 17% in those who received neoadjuvant therapy and 43% in those who did not, and concluded that neoadjuvant therapy did not increase the rate of BCS in ILC patients [24]. Tubiana Hulin et al. Reported the

**Figure 2:** (a) Inability to clearly assess cellular detail at surgical margins due to electrocautery artifact (x100, HE). (b) Demonstration of tumor cells by IHC method in permanent sections (x100, IHC Cytokeratin).

**Figure 3:** Possible tumoral cells similar to lymphocyte or stromal cells (Frozen Section, x200, H&E).

**Figure 4:** Freezing artifact: separation of adipose tissue and the painted surgical margin from fibrous tissue (arrow: fibrous tissue) (Frozen Section, x40; H&E).

**Figure 5:** Stromal cells (blue arrow), tumor cells (yellow arrow), and lymphocytes (red arrow) on a fibrous background after neoadjuvant therapy (x200; H&E).
rate of BCS at 47% and completion mastectomy at 34% in patients with ILC who received neoadjuvant therapy [23]. Lips et al., in their study examining the radiological response evaluation of neoadjuvant therapy in ILC and invasive ductal carcinoma cases, response in ILCs was mostly multinodular and diffuse, and they found mass-like contrast in only 13% of the cases [26]. Reidel et al., on the other hand, reported that neoadjuvant therapy is a factor that increases false negativity in intraoperative surgical margin evaluation, especially in nonpalpable lesions [17].

In our series, in accordance with the literature, the need for additional surgery, which was detected at a high rate has been interpreted as evidence that changes in ILCs secondary to neoadjuvant therapy complicate intraoperative pathological assessment.

5. Conclusion

The importance of the pathological perspective in the success of the BCS procedure, which has been frequently preferred recently, is clear. We would like to emphasize that this type of breast cancer may not be evaluated with Hematoxylin-Eosin stained preparations in the evaluation of surgical margins in permanent tissues in pathology practice and immunohistochemical methods can be applied, therefore intraoperative evaluation may result in high failure rates. Freezing artifacts and neoadjuvant treatment effects are other factors that increase this failure.

ILC is now recognized as a discrete disease process, and growing clinical evidence, particularly in the era of personalized therapy, indicates that treatment strategies based on TNM classification for all invasive breast carcinomas, regardless of pathological features are not optimal for specific subtypes such as ILC.

The major limitation of our study is that it is a retrospective study, but our case series consists of a team of specialist surgeons, pathologists, radiologists, and oncologists, and differences in patient management are minimal. We think that randomized prospective clinical studies are needed to determine the best treatment strategies specific to this tumor subtype.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

[1] E. A. Rakha, A. Patel, D. G. Powe et al., “Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast,” The American Journal of Surgical Pathology, vol. 34, no. 10, pp. 1472–1479, 2010 Oct.
[2] A. Mamtani, E. C. Zabor, L. H. Rosenberger, M. Stempel, M. L. Gemignani, and M. Morrow, “Was Re-excision less frequent in patients with lobular breast cancer after publication of the SSO-ASTRO margin guidelines,” Annals of Surgical Oncology, vol. 26, no. 12, pp. 3856–3862, 2019.
[3] F. Limaiaem, M. Khan, and S. Lotfollahzadeh, “Lobular breast carcinoma,” in StatPearls [Internet]. Treasure Island (FL) StatPearls Publishing, Treasure Island, FL, USA, 2022.
[4] A. E. McClnt Reed, L. Kalinowski, P. T. Simpson, and S. R. Lakhani, “Invasive lobular carcinoma of the breast: the increasing importance of this special subtype,” Breast Cancer Research, vol. 23, no. 1, p. 6, 2021.
[5] T. Sachaniński and B. Radecka, “Przegląd metod śródroperacyjnej oceny marginesów w chirurgicznym leczeniu oszczędzającym gruczoł piersiowy,” Nowotwory. Journal of Oncology, vol. 71, no. 4, pp. 225–231, 2021.
[6] T. Nowikiewicz, E. Śrutke, I. Glowacka-Mrotek, M. Tarkowska, A. Żyromska, and W. Zegarski, “Clinical outcomes of an intraoperative surgical margin assessment using the fresh frozen section method in patients with invasive breast cancer undergoing breast-conserving surgery a single center analysis,” Scientific Reports, vol. 9, no. 1, Article ID 134441, 2019.
[7] R. Laucirica, “Intraoperative assessment of the breast: guidelines and potential pitfalls,” Archives of Pathology & Laboratory Medicine, vol. 129, no. 12, pp. 1565–1574, 2005.
[8] M. S. Moran, S. J. Schnitt, A. E. Giuliano et al., “Society of Surgical Oncology–American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 88, no. 3, pp. 553–564, 2014.
[9] M. A. Chung, B. Cole, H. J. Wanebo, K. I. Bland, and H. R. Chang, “Optimal surgical treatment of invasive lobular carcinoma of the breast,” Annals of Surgical Oncology, vol. 4, no. 7, pp. 545–550, 1997.
[10] D. J. Winchester, H. R. Chang, T. A. Graves, H. R. Menck, K. I. Bland, and D. P. Winchester, “A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and Outcomes 11 This study was supported by the American cancer society and the American college of surgeons,” Journal of the American College of Surgeons, vol. 186, no. 4, pp. 416–422, 1998.
[11] N. Biglia, F. Maggiorotto, V. Liberale et al., “Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC),” European Journal of Surgical Oncology, vol. 39, no. 5, pp. 455–460, 2013.
[12] I. T. Rubio, M. Ahmed, T. Kovacs, and V. Marco, “Margins in breast conserving surgery: a practice-changing process,” European Journal of Surgical Oncology, vol. 42, no. 5, pp. 631–640, 2016.
[13] L. G. Wilke, T. Czechura, C. Wang et al., “Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma: a report from the National Cancer Data Base, 2004–2010,” JAMA Surgery, vol. 149, no. 12, pp. 1296–1305, 2014.
[14] K. C. Hewett, P. Müller, M. Piper et al., “Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: incidence and management strategies,” The American Journal of Surgery, vol. 223, no. 4, pp. 699–704, 2022.
[15] S. Sheereen, F. D. Lobo, B. Kumar et al., “Histopathological changes in breast cancers following neoadjuvant chemotherapy: implications for assessment of therapy-induced cytological and stromal changes for better clinical outcome and
effective patient care asian," JAMA Oncology, vol. 4, pp. 61–68, 2018.

[16] K. Esbona, Z. Li, and L. G. Wilke, “Intraoperative imprint cytology and frozen section pathology for margin assessment in breast conservation surgery: a systematic review." Annals of Surgical Oncology, vol. 19, no. 10, pp. 3236–3245, 2012.

[17] O. Riedl, F. Fitzal, N. Mader et al., “Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer,” European Journal of Surgical Oncology, vol. 35, no. 3, pp. 264–270, 2009.

[18] R. A. Mukhtar, “Editorial: applying margin consensus guidelines to invasive lobular carcinoma of the breast," Annals of Surgical Oncology, vol. 26, no. 12, pp. 3798-3799, 2019.

[19] M. L. Piper, J. Wong, K. Fahrner-Scott et al., “Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast," NPJ Breast Cancer, vol. 5, no. 1, 2019.

[20] A. Purushotham, S. Pinder, M. Cariati, M. Harries, and A. Goldhirsch, “Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3552–3554, 2010 Aug 1.

[21] D. J. O’Connor, M. G. Davey, L. R. Barkley, and M. J. Kerin, “Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery- A systematic review and meta-analysis,” The Breast, vol. 61, pp. 1–10, 2022 Feb.

[22] M. Cristofanilli, A. Gonzalez-Angulo, N. Sneige et al., “Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes [published correction appears in Journal of Clinical Oncology. 2013; 31(23): 2977. Buchholz, Thomas A [corrected to Buchholz, Thomas A]],” Journal of Clinical Oncology, vol. 23, no. 1, pp. 41–48, 2005.

[23] M. Tubiana-Hulin, D. Stevens, S. Lasry et al., “Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution," Annals of Oncology, vol. 17, no. 8, pp. 1228–1233, 2006.

[24] J. C. Boughey, J. Wagner, B. J. Garrett et al., “Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation," Annals of Surgical Oncology, vol. 16, no. 6, pp. 1606–1611, 2009.

[25] J. K. Lopez and L. W. Bassett, “Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings,” Radio Graphics, vol. 29, no. 1, pp. 165–176, 2009.

[26] E. H. Lips, R. A. Mukhtar, C. Yau et al., "Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer," Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 35–43, 2012.